{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:53:44Z","timestamp":1759334024789,"version":"build-2065373602"},"reference-count":107,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015900","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:22:43Z","timestamp":1759227763000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose reduction and discontinuation of conventional synthetic disease-modifying anti-rheumatic drugs (DMARDs) for people with rheumatoid arthritis or psoriatic arthritis in remission or low disease activity"],"prefix":"10.1002","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-1697","authenticated-orcid":false,"given":"Huai Leng","family":"Pisaniello","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel L","family":"Whittle","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"},{"name":"Rheumatology Unit; Queen Elizabeth Hospital; Woodville South Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renea V","family":"Johnston","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Glennon","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesl","family":"Grobler","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila","family":"Cyril","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anneliese D","family":"Arno","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"School of Public Health and Preventive Medicine; Monash University; Melbourne Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"issue":"13","key":"10.1002\/14651858.CD015900-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015900-BIB0002|cit2","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nature Reviews Disease Primers"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"ITC1","DOI":"10.7326\/AITC201901010","article-title":"Rheumatoid arthritis","volume":"170","author":"Sparks","year":"2019","journal-title":"Annals of the Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015900-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/S2665-9913(23)00211-4","article-title":"Global, regional, and national burden of rheumatoid arthritis, 1990\u20132020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"GBD 2021 Rheumatoid Arthritis Collaborators","year":"2023","journal-title":"Lancet Rheumatology"},{"issue":"23","key":"10.1002\/14651858.CD015900-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"16","key":"10.1002\/14651858.CD015900-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1056\/NEJM197804202981602","article-title":"Association of the B-cell alloantigen DRw4 with rheumatoid arthritis","volume":"298","author":"Stastny","year":"1978","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1136\/ard.61.4.290","article-title":"Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide","volume":"61","author":"Emery","year":"2002","journal-title":"Annals of Rheumatic Disease"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015900-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"e000064","DOI":"10.1136\/rmdopen-2015-000064","article-title":"Structural integrity versus radiographic progression in rheumatoid arthritis","volume":"1","author":"Favalli","year":"2015","journal-title":"RMD Open"},{"issue":"11","key":"10.1002\/14651858.CD015900-BIB0010|cit10","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis & Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD015900-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism Collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/annrheumdis-2013-203284","article-title":"Performance of the 2010 ACR\/EULAR classification criteria for rheumatoid arthritis: a systematic literature review","volume":"73","author":"Radner","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD015900-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.1093\/rheumatology\/keae198","article-title":"The worldwide prevalence of psoriatic arthritis \u2013 a systematic review and meta-analysis","volume":"63","author":"Lembke","year":"2024","journal-title":"Rheumatology (Oxford, England)"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","article-title":"Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis","volume":"48","author":"Scotti","year":"2018","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD015900-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1002\/acr.22831","article-title":"Global prevalence of spondyloarthritis: a systematic review and meta-regression analysis","volume":"68","author":"Stolwijk","year":"2016","journal-title":"Arthritis Care & Research"},{"key":"10.1002\/14651858.CD015900-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The epidemiology of psoriatic arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"10","key":"10.1002\/14651858.CD015900-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD015900-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"i4","DOI":"10.1093\/rheumatology\/kez325","article-title":"The many faces of psoriatic arthritis: their genetic determinism","volume":"59","author":"Winchester","year":"2020","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"238","key":"10.1002\/14651858.CD015900-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/oxfordjournals.qjmed.a068085","article-title":"Psoriatic arthritis (PSA) \u2013 an analysis of 220 patients","volume":"62","author":"Gladman","year":"1987","journal-title":"Quarterly Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/rheumatology\/30.4.245","article-title":"Psoriatic arthritis (PA): a clinical, Immunological and radiological study of 180 patients","volume":"30","author":"Torre Alonso","year":"1991","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.berh.2012.01.003","article-title":"Psoriatic arthritis","volume":"26","author":"Duarte","year":"2012","journal-title":"Best Practice & Research Clinical Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD015900-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1002\/art.34536","article-title":"Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"64","author":"Coates","year":"2012","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD015900-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis and Rheumatism"},{"issue":"3 Suppl 59","key":"10.1002\/14651858.CD015900-BIB0026|cit26","first-page":"S32","article-title":"The impact of rheumatoid arthritis and treatment on patients' lives","volume":"28","author":"Strand","year":"2010","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD015900-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","article-title":"Quality of life in psoriatic arthritis","volume":"14","author":"Gudu","year":"2018","journal-title":"Expert Review of Clinical Immunology"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0028|cit28","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.semarthrit.2017.05.010","article-title":"The psychosocial burden of psoriatic arthritis","volume":"47","author":"Husni","year":"2017","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"8","key":"10.1002\/14651858.CD015900-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s00296-024-05574-9","article-title":"Longitudinal effects of affective distress on disease outcomes in rheumatoid arthritis: a meta-analysis and systematic review","volume":"44","author":"Sweeney","year":"2024","journal-title":"Rheumatology International"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.berh.2015.06.001","article-title":"Rheumatoid arthritis and work: the impact of rheumatoid arthritis on absenteeism and presenteeism","volume":"29","author":"Verstappen","year":"2015","journal-title":"Best Practice & Research: Clinical Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD015900-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3899\/jrheum.140259","article-title":"Work productivity loss and fatigue in psoriatic arthritis","volume":"41","author":"Walsh","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0032|cit32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2013-204317","article-title":"Proposal for a new nomenclature of disease-modifying antirheumatic drugs","volume":"73","author":"Smolen","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015900-BIB0033|cit33","unstructured":"Australia and New Zealand Musculoskeletal Clinical Trials Network An Australian living guideline for the pharmacological management of inflammatory arthritis (v4.10) https:\/\/app.magicapp.org\/#\/guideline\/LqRV3n"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis & Rheumatology"},{"issue":"12","key":"10.1002\/14651858.CD015900-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3899\/jrheum.181165","article-title":"Patient preferences for disease-modifying antirheumatic drug treatment in rheumatoid arthritis: a systematic review","volume":"47","author":"Durand","year":"2020","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD015900-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/rheumatology\/kew280","article-title":"Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment","volume":"55","author":"Hazlewood","year":"2016","journal-title":"Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0038|cit38","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1136\/annrheumdis-2013-204020","article-title":"Time trends in disease activity, response and remission rates in rheumatoid arthritis during the past decade: results from the NOR-DMARD study 2000\u20132010","volume":"74","author":"Aga","year":"2015","journal-title":"Annals of Rheumatic Disease"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00393-015-0019-5","article-title":"Clinical remission in rheumatoid arthritis. Data from the early arthritis cohort study CAPEA","volume":"75","author":"Albrecht","year":"2016","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"6","key":"10.1002\/14651858.CD015900-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1093\/rheumatology\/ken059","article-title":"Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs","volume":"47","author":"Cantini","year":"2008","journal-title":"Rheumatology (Oxford, England)"},{"issue":"10","key":"10.1002\/14651858.CD015900-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.3899\/jrheum.121515","article-title":"Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort","volume":"40","author":"Combe","year":"2013","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD015900-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10067-014-2546-x","article-title":"Indispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohort","volume":"33","author":"Nikiphorou","year":"2014","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/ard.2010.139774","article-title":"Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register","volume":"70","author":"Soliman","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD015900-BIB0044|cit44","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/imj.15816","article-title":"Australian recommendations on tapering of biologic and targeted synthetic disease-modifying anti-rheumatic drugs in inflammatory arthritis","volume":"52","author":"Whittle","year":"2022","journal-title":"Internal Medicine Journal"},{"issue":"6","key":"10.1002\/14651858.CD015900-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Annals of Rheumatic Disease"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0046|cit46","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015900-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010455.pub3","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","author":"Verhoef","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"40","key":"10.1002\/14651858.CD015900-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s10067-020-05363-2","article-title":"Systematic review of recommendations on the use of methotrexate in rheumatoid arthritis","volume":"40","author":"Valerio","year":"2021","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0050|cit50","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1093\/rheumatology\/keac515","article-title":"Withdrawal of MTX in rheumatoid arthritis patients on bDMARD\/tsDMARD plus methotrexate at target: a systematic review and meta-analysis","volume":"62","author":"Wang","year":"2023","journal-title":"Rheumatology"},{"issue":"4-5","key":"10.1002\/14651858.CD015900-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.berh.2015.09.006","article-title":"De-intensifying treatment in established rheumatoid arthritis (RA): why, how, when and in whom can DMARDs be tapered?","volume":"29","author":"Fautrel","year":"2015","journal-title":"Best Practice & Research. Clinical Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0052|cit52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.semarthrit.2019.06.001","article-title":"Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: a systematic review and network meta-analysis","volume":"49","author":"Lu","year":"2019","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0053|cit53","doi-asserted-by":"publisher","first-page":"e002074","DOI":"10.1136\/rmdopen-2021-002074","article-title":"Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes","volume":"8","author":"McInnes","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3899\/jrheum.121306","article-title":"Updated method guidelines for Cochrane musculoskeletal group systematic reviews and metaanalyses","volume":"41","author":"Ghogomu","year":"2014","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD015900-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jclinepi.2017.08.010","article-title":"Living systematic reviews: 1. Introduction \u2013 the why, what, when and how","volume":"91","author":"Elliott","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015900-BIB0056|cit56","unstructured":"Higgins JP Lasserson T Thomas J Flemyng E Churchill R Methodological expectations of Cochrane intervention reviews. Cochrane: London, Version August 2023 Available from https:\/\/community.cochrane.org\/mecir-manual"},{"key":"10.1002\/14651858.CD015900-BIB0057|cit57","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis and Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0059|cit59","first-page":"175","article-title":"1958 Revision of diagnostic criteria for rheumatoid arthritis","volume":"9","author":"Ropes","year":"1958","journal-title":"Bulletin of Rheumatic Disease"},{"issue":"Suppl 39","key":"10.1002\/14651858.CD015900-BIB0060|cit60","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clinical and Experimental Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0061|cit61","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","article-title":"American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"70","author":"Felson","year":"2011","journal-title":"Annals of Rheumatic Disease"},{"issue":"5 Suppl 39","key":"10.1002\/14651858.CD015900-BIB0062|cit62","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clinical Experimental Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","article-title":"A simplified disease activity index for rheumatoid arthritis for use in clinical practice","volume":"42","author":"Smolen","year":"2003","journal-title":"Rheumatology (Oxford, England)"},{"issue":"7","key":"10.1002\/14651858.CD015900-BIB0064|cit64","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care & Research (Hoboken)"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0065|cit65","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3899\/jrheum.150826","article-title":"Defining low disease activity states in psoriatic arthritis using novel composite disease instruments","volume":"43","author":"Coates","year":"2016","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD015900-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Annals of Rheumatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD015900-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD015900-BIB0068|cit68","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1186\/1745-6215-14-324","article-title":"Outcome measures in rheumatoid arthritis randomised trials over the last 50 years","volume":"14","author":"Kirkham","year":"2013","journal-title":"Trials"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015900-BIB0069|cit69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3899\/jrheum.2023-0530","article-title":"Initiating evaluation of composite outcome measures for psoriatic arthritis: 2022 updates from the GRAPPA-OMERACT working group","volume":"50","author":"Leung","year":"2023","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0070|cit70","first-page":"511","article-title":"Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis","volume":"24","author":"Husted","year":"1997","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD015900-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Sherbourne","year":"1992","journal-title":"Medical Care"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0072|cit72","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1002\/14651858.CD015900-BIB0073|cit73","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1477-7525-1-54","article-title":"The Health Utilities Index (HUI): concepts, measurement properties and applications","volume":"1","author":"Horsman","year":"2003","journal-title":"Health and Quality of Life Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1002\/art.1780230203","article-title":"Measuring health status in arthritis. The Arthritis Impact Measurement Scales","volume":"23","author":"Meenan","year":"1980","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD015900-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/rheumatology\/36.8.884","article-title":"Quality of life in rheumatoid arthritis","volume":"36","author":"Whalley","year":"1997","journal-title":"British Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0077|cit77","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1046\/j.1365-2133.2003.05492.x","article-title":"Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials","volume":"149","author":"McKenna","year":"2003","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0078|cit78","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1136\/ard-2023-224742","article-title":"Definition of rheumatoid arthritis flare based on SDAI and CDAI","volume":"83","author":"Konzett","year":"2024","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/03009747509165261","article-title":"A radiological method for grading the severity of rheumatoid arthritis","volume":"4","author":"Larsen","year":"1973","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD015900-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/art.1780140605","article-title":"Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities","volume":"14","author":"Sharp","year":"1971","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0081|cit81","first-page":"261","article-title":"How to read radiographs according to the Sharp\/van der Heijde method","volume":"27","author":"Heijde","year":"2000","journal-title":"Journal of Rheumatology"},{"issue":"3","key":"10.1002\/14651858.CD015900-BIB0082|cit82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s003930170064","article-title":"A method to score radiographic change in psoriatic arthritis","volume":"60","author":"Wassenberg","year":"2001","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"2","key":"10.1002\/14651858.CD015900-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1002\/art.1780230202","article-title":"Measurement of patient outcome in arthritis","volume":"23","author":"Fries","year":"1980","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD015900-BIB0084|cit84","unstructured":"Brooker J Synnot A McDonald S Elliott J Turner T Guidance for the production and publication of Cochrane living systematic reviews: Cochrane reviews in living mode (version 1.0; December 2019) https:\/\/community.cochrane.org\/review-development\/resources\/living-systematic-reviews"},{"key":"10.1002\/14651858.CD015900-BIB0085|cit85","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Technical Supplement to Chapter 4: Searching for and selecting studies (chapter last updated September 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015900-BIB0086|cit86","unstructured":"EndNote Clarivate 2023"},{"key":"10.1002\/14651858.CD015900-BIB0087|cit87","unstructured":"Covidence Veritas Health Innovation 2024"},{"key":"10.1002\/14651858.CD015900-BIB0088|cit88","unstructured":"Welch VA Petkovic J Jull J Hartling L Klassen T Kristjansson E Chapter 16: Equity and specific populations (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jclinepi.2013.08.005","article-title":"Applying an equity lens to interventions: using PROGRESS ensures consideration of socially stratifying factors to illuminate inequities in health","volume":"67","author":"O'Neill","year":"2014","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015900-BIB0090|cit90","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1186\/1471-2458-13-658","article-title":"The grounded psychometric development and initial validation of the Health Literacy Questionnaire (HLQ)","volume":"13","author":"Osborne","year":"2013","journal-title":"BMC Public Health"},{"key":"10.1002\/14651858.CD015900-BIB0091|cit91","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"key":"10.1002\/14651858.CD015900-BIB0092|cit92","unstructured":"WebPlotDigitizer Rohatgi A Ankit Rohatgi 2021"},{"key":"10.1002\/14651858.CD015900-BIB0093|cit93","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017 Available from https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/archive\/v5.2.0"},{"key":"10.1002\/14651858.CD015900-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jclinepi.2012.08.001","article-title":"GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles \u2013 continuous outcomes","volume":"66","author":"Guyatt","year":"2013","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015900-BIB0095|cit95","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015900-BIB0096|cit96","unstructured":"Higgins JP Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015900-BIB0097|cit97","unstructured":"Deeks JJ Higgins JP Altman DG McKenzie JE Veroniki AA Chapter 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/www.cochrane.org\/handbook"},{"issue":"7109","key":"10.1002\/14651858.CD015900-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD015900-BIB0099|cit99","unstructured":"Page MJ Higgins JP Sterne JA Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis (chapter last updated August 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5. Cochrane, 2024 Available from https:\/\/cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD015900-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/acr.20349","article-title":"Reaching those most in need: a scoping review of interventions to improve health care quality for disadvantaged populations with osteoarthritis","volume":"63","author":"Borkhoff","year":"2011","journal-title":"Arthritis Care & Research"},{"issue":"4","key":"10.1002\/14651858.CD015900-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/heapro\/13.4.349","article-title":"Health promotion glossary","volume":"13","author":"World Health Organization","year":"1998","journal-title":"Health Promotion International"},{"key":"10.1002\/14651858.CD015900-BIB0102|cit102","unstructured":"Institute of Medicine (US) Committee on Health Literacy; Nielsen-Bohlman L Panzer AM Kindig DA Health Literacy: A Prescription to End Confusion. Washington (DC): National Academies Press (US); 2004 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK216032"},{"key":"10.1002\/14651858.CD015900-BIB0103|cit103","unstructured":"Commonwealth of Australia A healthier future for all Australians \u2013 final report of the National Health and Hospitals Reform Commission \u2013 June 2009 https:\/\/apo.org.au\/node\/17921"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD015900-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10810730.2010.499996","article-title":"Health literacy and the Millennium Development Goals: United Nations Economic and Social Council (ECOSOC) regional meeting background paper (abstracted)","volume":"15","author":"United Nations Economic and Social Council (ECOSOC)","year":"2010","journal-title":"Health Communication in Healthcare"},{"key":"10.1002\/14651858.CD015900-BIB0105|cit105","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD015900-BIB0106|cit106","unstructured":"Australia and New Zealand Musculoskeletal Clinical Trials Network Australian Living Guidelines https:\/\/anzmusc.org\/outputs\/australian-living-guidelines\/"},{"key":"10.1002\/14651858.CD015900-BIB0107|cit107","unstructured":"Buchbinder R Expert Advisory Guideline Development Panel An Australian living guideline for the pharmacological management of inflammatory arthritis Available from https:\/\/app.magicapp.org\/#\/guideline\/LqRV3n"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T10:22:52Z","timestamp":1759227772000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015900"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":107,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015900","relation":{},"ISSN":["1465-1858"],"issn-type":[{"type":"electronic","value":"1465-1858"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}